

ADVANCED INNOVATION PROGRAMME ON HEALTH TECHNOLOGY ASSESSMENT (AIP-HTA)

WORK PROGRAMME 2013

Main objective

The programme's principal objective is to identify ways to optimise added-value to patients' organisations, science and industry in the field of health technology assessment (*HTA*) as a multi-stakeholder think tank focusing on innovation. The overwhelming consensus from all those consulted so far is to examine the question:

"How can societal benefits be integrated in National Health Technology Assessment in a way which positively contributes to the realisation of better health outcomes for EU citizens as well as a smart sustainable economy?"

Main highlights of AIP-HTA

I. *Epposi HTA domains for a societal benefits approach to HTA:*

Value

HTA methods (which methodologies are used for HTA assessment)

- HTA methodologies;
- Assessment.

HTA content (which criteria should be assessed in HTA)

- Patient-defined outcomes;
- Psychological aspects;
- Workability/Continued Economic Activity;
- Ethical Aspects;
- Significant Others.

HTA process (who is involved and what should be considered in the decision-making)

- Governance
- All stakeholder involvement
- Cross-sectoral policy making

II. *Case studies to illustrate interesting and best practice examples*

In order to validate proposed domains and sub-domains of Epposi societal benefits framework, four case studies were evaluated:

- AGNSS (ultra orphan drugs) approach in UK;
- Conditional reimbursement in the Netherlands;
- Workability/continued economic activity in Sweden;
- Medical devices in Germany.

The evaluation of the case studies was equally followed by mapping of current HTA practices in 4 selected EU countries as well as of EUnetHTA core model. The outcomes of the mapping exercise directly feed into the definitions-building of Epposi Societal Benefits approach to HTA

Work programme priorities for 2013

Following on from the work in 2012 whereby HTA experts and stakeholders from Epposi and beyond completed a taxonomy for a societal benefits approach to HTA followed up by case studies to examine best and interesting practices related to the domains identified, the 2013 objectives will focus on finalization of building an ideal model through evidence and consensus building followed by an emphasis on wider acceptance of the model as strongly advocated by the group.

We will:

Reach consensus between stakeholders on the ideal model

- Explore in two studies issues arising in relation to the practical implementation of such a model at national and European levels in relation to citizens and public authorities.
- Seek endorsement of the Epposi work from other HTA specialist groups (HTAi, ISPOR and EUNetHTA)
- Establishment of the ISPOR Special Interest Group on Rare Diseases and HTA

Throughout the year, we will also seek wide awareness raising, valorisation, acknowledgment and acceptance of the precepts being worked on in the wider HTA community.

Key policy areas to engage

As a result of the 2012 orientations of the AIP-HTA, the core policy areas for its engagement are:

- Implications of Article 15 of the Cross-Border Directive, the work of the HTA-related Directorate (DG SANCO) and the expansion of the importance of EUNetHTA;
- DG EAC (in relation to citizen's empowerment as part of the HTA democratic decision-making processes);
- DG RTD (growing focus on stakeholder engagement and science and society and with a focus on the possible elements of the Horizon2020 programme).
- European Innovation Partnership (focus on active and healthy ageing);

Key outputs

In 2013 outputs will focus on applying the framework to the limits of medicine:

- Looking behind the health bubble - focus on prevention;
- Addressing silo mentality to support societal and environmental evaluation;
- Forwarding projection of health care budget impact.

As such, the Programme will deliver:

- HTA societal benefits model - framework and evidential documentation (March 2013);
- HTA societal benefits approach factsheets (easy to use versions) (April 2013);
- Study on Analysis of broader view of value (citizen-centered, societal impact, innovation) (May 2013);
- Study on analysing the issues of technology within the context of "macro HTA": Health system - fitness for purpose (Can the system incorporate technology?) (November 2013).

Events in 2013

- **Consensus workshop** to have a wider peer review and consensus on the full model (February 2013);
- **Web survey and qualitative interviews** to further identify "value" related to the Epposi framework;
- **Programming Day 2013** (April 2013);
- **Stakeholder Survey** on the definitions of Epposi's Societal Benefits Approach to HTA (April 2013);
- **Breakfast briefing** to launch the "Value" study (June 2013);

- Annual General Meeting (June 2013);
- White Paper on Epposi's Societal Benefits Approach to HTA (June 2013);
- Session on values at HTAi (June 2013);
- Web survey and qualitative interviews with HTA agencies, EUNetHTA and related stakeholders to analyse the issues of technology within the context of "macro HTA";
- Stakeholder Day 2013 - (September 2013);
- Breakfast briefing / session at ISPOR Europe (November 2013).

Key stakeholders to be engaged

- Academic involvement is to be enhanced (e.g., through a partnership with TU Delft) but also more widely (enlargement of other research and academic institutions as stakeholders);
- HTA national agencies and/or HTA bodies;
- HTA-related associations e.g., HTAi, The Euroqual Group;
- 1:1 national HTA agencies.

Communication and outreach

- We will publish a bi-monthly eNewsletter specifically dedicated to the AIP-HTA which covers updates on programme deliverables and also allows Programme participants to interact;
- We will hold **quarterly webinars** via skype and office 2010 whereby Programme participants have the opportunity to discuss a related topic;
- The Epposi **AIP-HTA LinkedIn group** will also be expanded as well as a social media campaign via Twitter;
- We will **seek to speak** or at the minimum have a poster exhibition of the Epposi work at the HTAi 2013 and ISPOR 2013 European conference;
- We will also work with other organizations to ensure that the **ISPOR Rare Disease and HTA Special Interest Group** are established.



Resources

In 2013, we have continued to have a close content delivery partnership between key Epposi stakeholders, academic knowledge partners (*IBMG Institute of Erasmus University, Rotterdam and Edelman|The Centre*) and the Epposi Secretariat core team supported by the expertise and knowledge of Epposi member organisations.

Resources have been in kind as well as financial. In order to focus on content delivery, we will seek additional funding from institutional donors in relation to conferences to be held as well as to fund some of the core research work looking towards 2013.

Knowledge Partners



Find out more and how to join the programme

Dr Andrea Pavlickova

Programme Manager
andrea.pavlickova@epposi.org
Tel: +32 2 503 1307

Jacqueline Bowman-Busato

Executive Director
jacqueline.bowman@epposi.org
Tel: +32 2 503 1307